Enzo Biochem Debt to Equity Ratio 2010-2023 | ENZ

Current and historical debt to equity ratio values for Enzo Biochem (ENZ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Enzo Biochem debt/equity for the three months ending January 31, 2023 was 0.01.
Enzo Biochem Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2023-01-31 $0.04B $0.03B 1.33
2022-10-31 $0.04B $0.05B 0.89
2022-07-31 $0.04B $0.05B 0.76
2022-04-30 $0.04B $0.06B 0.67
2022-01-31 $0.04B $0.07B 0.67
2021-10-31 $0.04B $0.07B 0.62
2021-07-31 $0.05B $0.07B 0.66
2021-04-30 $0.05B $0.07B 0.75
2021-01-31 $0.05B $0.06B 0.81
2020-10-31 $0.05B $0.06B 0.92
2020-07-31 $0.05B $0.06B 0.93
2020-04-30 $0.05B $0.06B 0.87
2020-01-31 $0.05B $0.07B 0.65
2019-10-31 $0.05B $0.08B 0.60
2019-07-31 $0.02B $0.09B 0.24
2019-04-30 $0.02B $0.09B 0.22
2019-01-31 $0.02B $0.07B 0.32
2018-10-31 $0.02B $0.08B 0.25
2018-07-31 $0.02B $0.08B 0.25
2018-04-30 $0.02B $0.09B 0.22
2018-01-31 $0.02B $0.09B 0.23
2017-10-31 $0.02B $0.09B 0.23
2017-07-31 $0.02B $0.09B 0.21
2017-04-30 $0.02B $0.09B 0.20
2017-01-31 $0.02B $0.09B 0.21
2016-10-31 $0.02B $0.09B 0.25
2016-07-31 $0.02B $0.09B 0.25
2016-04-30 $0.02B $0.05B 0.44
2016-01-31 $0.03B $0.05B 0.49
2015-10-31 $0.03B $0.05B 0.58
2015-07-31 $0.03B $0.04B 0.61
2015-04-30 $0.02B $0.03B 0.72
2015-01-31 $0.03B $0.04B 0.71
2014-10-31 $0.03B $0.04B 0.73
2014-07-31 $0.03B $0.04B 0.74
2014-04-30 $0.03B $0.04B 0.65
2014-01-31 $0.02B $0.03B 0.73
2013-10-31 $0.03B $0.03B 0.76
2013-07-31 $0.03B $0.03B 0.73
2013-04-30 $0.02B $0.04B 0.63
2013-01-31 $0.02B $0.04B 0.54
2012-10-31 $0.02B $0.05B 0.47
2012-07-31 $0.02B $0.05B 0.41
2012-04-30 $0.02B $0.08B 0.25
2012-01-31 $0.02B $0.08B 0.25
2011-10-31 $0.02B $0.08B 0.25
2011-07-31 $0.02B $0.09B 0.23
2011-04-30 $0.02B $0.09B 0.20
2011-01-31 $0.02B $0.09B 0.21
2010-10-31 $0.02B $0.10B 0.19
2010-07-31 $0.02B $0.10B 0.19
2010-04-30 $0.01B $0.10B 0.14
2010-01-31 $0.02B $0.11B 0.21
2009-10-31 $0.02B $0.12B 0.13
2009-07-31 $0.02B $0.12B 0.14
2009-04-30 $0.02B $0.12B 0.15
2009-01-31 $0.02B $0.12B 0.13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.106B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00